Destiny Pharma - XF-73 Nasal Readying For Phase III (Sponsored Research, TP £1.20, 7pgs)
With Destiny yet to strike a deal for XF-73 Nasal that would deliver sufficient value for shareholders, they have issued a strategic update to the market. The top priority is to advance XF-73 Nasal into Phase III studies, which they want to achieve by 2025. While a licensing deal is one possible route, the company is also considering a self-funded option. However, in the meantime, the Phase III study has been redesigned to address feedback from potential partners, cutting the projected cost by over half. Patients will be recruited from indications with higher rates of post-surgical infections and the study will be MRSA-enriched, improving its commercial attractiveness. We continue to forecast ~$1bn of non-risk adjusted peak sales for XF-73; runway is to Q1 2025.For access to the full note, please contact Naresh Chouhan ( )
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.